Peptides: What They Are, What the Science Actually Says, and What You Need to Know Before You Buy Anything
I've been seeing it everywhere lately.
In a local moms Facebook group I'm part of, a woman posts asking how to afford semaglutide. She's been on it, it's working, but her prescription is running out and the brand name is out of reach. Within minutes, someone is in the comments selling her peptides. Then another person. Then a link to a website. No context. No credentials. No caution. Just: here, buy this.
Something about that exchange stuck with me. It felt predatory — not because peptides are inherently dangerous, but because desperate people deserve real information, not a sales pitch from a stranger.
So I went deep. I listened to hours of podcasts, read through research papers and show notes, and fact-checked everything I could find. What I learned is that this is one of the most genuinely complicated topics in the wellness world right now. And complicated is exactly what those Facebook comment sections are not.
I want to be honest about where I'm coming from. I understand why people experiment — I've done it myself. When I knew more about perimenopause and hormone therapy than my own doctor, I educated myself, found a practitioner who would work with me, and made my own informed decisions. That kind of self-advocacy is something I believe in. But the key word is informed. And that's what's missing from most of this conversation.
I'll say one more thing before we dive in: the same week I was bothered by what I saw in that group, a friend and I were half-seriously talking about whether to try BPC-157 on her dog who had just had her ACL repaired. And honestly — if I tore my Achilles tomorrow, I'm not sure I wouldn't consider it myself.
That tension is the whole blog. Let's get into it.
I'm also working on a full deep-dive on GLP-1s next — the science, the culture, and the harder questions about what we're actually chasing. Consider this the foundation for that conversation.
What Is a Peptide?
A peptide is a short chain of amino acids. That's it.
Your body makes thousands of them naturally. They act as chemical messengers, hormones, and building blocks. Some of the most important things happening in your body right now are being coordinated by peptides.
Some you'll recognize: insulin is a peptide. Endorphins — the feel-good chemicals your brain releases during exercise — are peptides. GLP-1, the hormone that Ozempic mimics, is a peptide your gut produces naturally after you eat.
Amino acids are the individual building blocks the body uses to make all proteins. When a small number of them link together in a chain, we call it a peptide. When the chain gets much longer, we call it a protein. The line between the two is fuzzy, but "peptide" generally means something short and relatively simple in structure.
Here's why that simplicity matters: because peptides are small and straightforward, they're also easy to modify. Change one amino acid, swap out a salt form, tweak the structure slightly — and on paper, you have a different molecule. As you'll see, this is exactly how certain peptides have been quietly reinvented to get around regulatory restrictions. The molecule is essentially the same. The paperwork says otherwise.
The peptides people are talking about — BPC-157, semaglutide, retatrutide, TB-500 — span a huge range of evidence, legality, and risk. Treating them as one category is where most of the confusion starts.
How We Got Here: The GLP-1 Story
To understand the current peptide landscape, you first need to understand what happened with GLP-1 medications — because it set everything else in motion.
Semaglutide — the active ingredient in Ozempic and Wegovy — was an FDA-approved medication for type 2 diabetes and weight management. When demand exploded, supply couldn't keep up. Wegovy was added to the FDA's national drug shortage list in March 2022, Ozempic in August 2022.
Here's why that matters: under federal law, when a drug is officially declared in shortage, compounding pharmacies are legally permitted to make their own versions for patients. A compounding pharmacy is simply a licensed pharmacy that prepares customized medications — they've existed for decades, making things like dye-free versions of medications, or doses that aren't commercially available.
The shortage opened a massive door. Compounded semaglutide became available through telehealth platforms and medical spas for $150 to $300 a month, compared to over $1,000 for the brand name. For millions of people without insurance coverage, this was the only way in.
The FDA declared the semaglutide shortage resolved in February 2025. That declaration ended the legal basis for most compounding. Enforcement deadlines were set — April 2025 for smaller pharmacies, May 2025 for larger facilities. Warning letters went out. Major telehealth platforms exited the market.
Before we move on, something needs to be said plainly: Wegovy costs over $1,300 a month out of pocket. That's not a small barrier. The frustration driving people toward the grey market is real and legitimate. We'll get to legal ways to reduce costs. But that desperation is important context for everything that follows.
Know Your Pharmacy: 503A vs. 503B
If you're going to navigate any of this responsibly, this distinction matters — and almost no one explains it clearly.
503A pharmacies are state-licensed compounding pharmacies that make medications for individual patients, one prescription at a time. Think of them as the traditional neighborhood compounding pharmacy. They need a valid prescription with your name on it. They can't produce drugs in bulk or ship to anyone without a patient-specific prescription. They're regulated by state pharmacy boards rather than the FDA directly.
503B outsourcing facilities are larger operations. They can produce batches of medications in advance and distribute them to hospitals and clinics — without a separate prescription attached to each unit. They're registered with the FDA, subject to FDA inspections, and required to follow the same strict manufacturing standards as large pharmaceutical companies. As of late 2024, only about 86 facilities in the entire country were registered as 503B facilities.
Here's the part that almost every news article gets wrong: when a 503B facility is described as "FDA-inspected," that refers to the facility — not the drug it produces. Products made at a 503B facility are still not FDA-approved drugs. The building is regulated. The product is not. Those are two very different things.
For compounded GLP-1s specifically: 503A pharmacies can still legally compound semaglutide or tirzepatide when there's a documented clinical reason. Not just cost — an actual medical reason. Some real examples: a patient who is allergic to an inactive ingredient in the commercial version; someone who needs a lower starting dose than what's commercially available to help manage side effects; or a formulation that includes something like B12, which some providers add to help with the nausea these medications can cause. Cost alone doesn't satisfy the requirement under current FDA rules, though enforcement varies and many providers are working thoughtfully within this framework.
The bottom line: if you're pursuing any compounded medication, know which type of pharmacy you're working with. Ask for third-party testing documentation. Make sure you have a prescription from a provider who has actually evaluated you — not just a box you checked on a telehealth intake form.
BPC-157: The One Everyone Is Asking About
Body Protection Compound 157 — BPC-157 — is a synthetic peptide made up of 15 amino acids. It was reportedly derived from a protein found in human gastric juice, though the full sequence of that parent protein has never been published, and BPC-157 doesn't actually match any known peptide the human body makes. Its origin story is murky from the start.
It was first synthesized in the 1990s by a research team in Croatia led by Dr. Predrag Sikiric, who has studied it for roughly 50 years. The claims are wide-ranging: faster healing of tendons, ligaments, and muscle; gut repair; reduced inflammation; pain relief; even neuroprotection. The list keeps growing depending on who you ask.
Here's what the data actually shows.
The animal research is real and genuinely interesting. Over 100 peer-reviewed studies exist on BPC-157 — mostly conducted in rats and dogs. They consistently show positive effects on wound healing, tendon repair, and gut health. BPC-157 appears to stimulate the growth of new blood vessels at injury sites, which would logically help speed healing. It's a compelling body of research.
There are two significant problems with it. First, almost all of it comes from the same research group in Croatia. Independent replication — other labs, other countries, other researchers confirming the findings — is nearly nonexistent in science, that's a meaningful limitation. Second, we have almost no idea how any of this translates to humans.
The human data is almost nothing. A 2025 systematic review — a study that gathered and analyzed all available research — screened over 500 studies and found exactly one qualifying human study: a 12-patient case series. There were also two early-stage clinical trials for ulcerative colitis conducted in Croatia in the early 2000s, but neither was ever fully published. A Phase I safety trial in healthy volunteers was completed, and the results have never been posted. That trial has been listed as "unknown status" for over a decade.
To put it plainly: there are zero completed, peer-reviewed, randomized controlled trials for BPC-157 in humans. For a compound that has been around for 30 years with claims this sweeping, that absence is significant.
What about the lethal dose? One thing the BPC-157 community often points to is that researchers have been unable to find a lethal dose in animal studies — meaning they couldn't determine the amount that would kill 50% of test animals, which is a standard safety benchmark used for any drug. This is genuinely interesting and does suggest an unusually wide safety margin. It also exists entirely in animal data. We simply don't know what it means in humans.
The legal back-and-forth. BPC-157 has been on the World Anti-Doping Agency's (WADA) banned substance list since January 2022 — meaning any competitive athlete subject to drug testing cannot use it, in season or out. The FDA classified it as a Category 2 substance in October 2023. Category 2 means the FDA has determined there isn't sufficient evidence of safety to permit its use — in humans or animals. Compounds in this category are legally sold only as research chemicals, labeled "not for human or animal consumption." That label is the legal technicality that keeps the market alive, even though everyone involved understands what people are actually doing with them. Category 2 classification also effectively blocked licensed compounding pharmacies from preparing it.
Then in February 2026, HHS Secretary RFK Jr. announced that BPC-157 would be among 14 peptides moving back to Category 1 — restoring the ability for compounding pharmacies to prepare it with a valid doctor's prescription. As of this writing, the formal FDA list update hasn't been published, so the status is still in transition. The WADA ban remains completely separate from the FDA classification — athletes subject to drug testing cannot use BPC-157 regardless of what the FDA does.
The amino acid loophole. When BPC-157 was placed on the FDA's Category 2 list in 2023, something called Pentadeca Arginate — or PDA — quickly appeared on the market. It has the same 15-amino-acid sequence as BPC-157, just a different salt form. The argument was that this made it a technically different molecule, outside the scope of the ban. Most healthcare attorneys who have analyzed this disagree. No FDA guidance has ever formally distinguished PDA from BPC-157. And yet PDA is currently being sold through telehealth-enabled compounding pharmacies at $325 to $400 per vial — five to ten times the grey market price of BPC-157 before the ban. The loophole is expensive.
The veterinary angle — and the honest personal one. Veterinarians appear to be considerably more willing to experiment with BPC-157 than physicians, and it has become fairly normalized for post-surgical recovery and tendon injuries in animals. There's a logic to this that I find hard to argue with: the overwhelming majority of BPC-157's research was conducted in animals — specifically rats and dogs. In a very real sense, veterinarians are working with exactly the population the research was done on. The safety profile across those studies has been remarkably consistent, and the results compelling enough that its use has moved from experimental to somewhat routine in certain veterinary practices.
Which brings me back to my friend's dog.
We were half-joking. But also, not entirely. The anecdotal reports in humans are compelling. People with chronic injuries who had tried everything are saying this worked. I'm not dismissing that. I'm also not able to explain why, because the science isn't there yet. What I know is that if I were facing something serious — exhausted from conventional options, looking at a long recovery — I would want every piece of information in this blog before I made that call. Not just the hopeful parts.
Retatrutide: Please Wait on This One
Retatrutide is Eli Lilly's next-generation weight loss drug. It targets three different hormone receptors simultaneously — GLP-1, GIP, and glucagon — which is why it's called a triple-agonist. The Phase 3 trial data has been extraordinary: one trial reported 28.7% weight loss, the highest result ever recorded in an obesity drug trial. People are very excited, and understandably so.
It is not FDA-approved. As of June 2026, the formal drug application hasn't even been filed yet. It is still completing Phase 3 trials — the large-scale human studies required before any drug can be approved. The earliest realistic approval window is late 2027. There is no legal compounding pathway for retatrutide because it has never been an approved drug, which means it can never have been on a shortage list.
People buying retatrutide right now are purchasing a drug that is still mid-clinical trial, from unregulated sources, reconstituting it themselves at home, and injecting it with no medical supervision of any kind. If what you're looking for is an advanced, effective GLP-1 medication right now, tirzepatide — the active ingredient in Mounjaro and Zepbound — is FDA-approved, available, and producing average weight loss results of around 20%. That is not a consolation prize. Wait for retatrutide to complete the process it's in.
Where It All Actually Comes From
Here's the part that genuinely surprises most people: virtually all grey market peptides originate from manufacturers in China — including grey market versions of FDA-approved drugs like semaglutide and tirzepatide.
This is not a political statement. China is the world's dominant manufacturer of pharmaceutical-grade peptide ingredients, including compounds used by legitimate pharmaceutical companies worldwide. The issue isn't the country of origin. The issue is what happens when those ingredients move through completely unregulated supply chains on their way to you.
The typical pathway looks like this: a Chinese manufacturer sells bulk peptide powder through direct contacts or platforms like Alibaba. A U.S.-based seller imports the powder, sometimes tests it, and repackages it into small vials. Those vials arrive labeled "for research use only" — a phrase that functions as a legal shield while everyone involved understands what it actually means. The buyer adds sterile water, draws the solution into a syringe, and injects it.
When someone tells you their peptides are "made in the USA" or "domestically sourced," what they almost certainly mean is that a U.S. company repackaged them. Building and operating a domestic peptide manufacturing facility requires millions of dollars, specialized equipment, and ongoing regulatory compliance. The economics simply don't support it. Domestic sellers add value through testing, customer service, and accountability. They almost never manufacture the compound themselves.
To give you a sense of scale: U.S. customs data showed that imports of hormone and peptide compounds from China reached $328 million in the first three quarters of 2025 alone — nearly double the same period the year before. This market is growing far faster than any regulatory framework can track it.
What Testing Can and Can't Tell You
Some grey market vendors do provide certificates of analysis from third-party laboratories, and some independent organizations purchase peptides on the open market and run them through sophisticated analytical testing to confirm what's actually in them. This is meaningfully better than nothing.
But here's what that testing typically covers: identity, purity, and approximate quantity. In other words — is the right molecule present, and roughly how much of it is there?
Here's what it doesn't cover: whether the product is sterile (free from bacteria and other contaminants), whether it contains endotoxins (toxic byproducts from bacteria that can cause serious systemic reactions even in tiny amounts), whether the peptide will remain stable once you add water to reconstitute it, whether it stayed stable during shipping and storage, and whether every vial in a batch matches the one that was actually tested.
Peptides are chemically fragile. They clump together, break down, and degrade with heat and temperature changes. A clear vial does not mean an intact, safe product.
This is the fundamental difference between a pharmaceutical product and a grey market one. It isn't just about whether the right molecule is present. It's about whether every single step — manufacturing, testing, storage, shipping, and handling — was controlled to a standard that makes it safe to inject into a human body.
Legal Ways to Reduce the Cost
I don't want to leave anyone with "just pay $1,300 a month" as the only answer. Here are real options:
For GLP-1s:
Novo Nordisk and Eli Lilly both offer manufacturer savings cards. For patients with commercial insurance, these can bring monthly costs down to around $25. GoodRx and similar discount platforms can also make a real difference at certain pharmacies.
There are now two FDA-approved oral GLP-1 options worth knowing about. Oral semaglutide — an oral version of Wegovy — was approved in December 2025. Orforglipron (brand name Foundayo) was approved in April 2026, available from $149 a month for self-pay patients. Worth noting: orforglipron is actually a small molecule, not a peptide — it just works on the same GLP-1 pathway. Both oral options produce somewhat more modest weight loss results than the injectable versions, but they're real, regulated medications at significantly lower price points.
Medicare Part D patients may be able to access Foundayo for $50 a month beginning July 2026. And if you're interested in retatrutide specifically, enrolling in one of Eli Lilly's ongoing clinical trials provides the drug at no cost with full medical supervision.
503A compounding pharmacies can still legally provide compounded semaglutide or tirzepatide for patients with a documented clinical reason. Work with a provider who can support that conversation appropriately.
For BPC-157:
With the anticipated reclassification back to Category 1, licensed compounding pharmacies should soon be able to prepare BPC-157 with a valid prescription. That pathway — a real provider relationship, a regulated pharmacy, documented oversight — is meaningfully different from buying a vial from a website and figuring it out alone. It takes more effort to access, but it puts you inside a system that has accountability built into it.
The Question Worth Sitting With
I want to end here, and I'll return to this more fully in the GLP-1 blog.
When we talk about these drugs and peptides — especially the ones marketed for weight loss — it's worth asking honestly: what are we actually going after? For some people the answer is genuinely metabolic health. Better blood sugar, lower cardiovascular risk, addressing real clinical conditions. The research on those goals is solid and the benefits are meaningful.
But some of what I see in those Facebook groups is people in real pain, chasing something they've been told will fix them, buying it from a stranger because the actual medication costs more than their rent. That gap — between what people need and what the system makes accessible — is being exploited. That's worth naming.
I'm not here to tell anyone what to do with their own body. I never have been. What I want is for every person making these decisions to have the actual information — where it comes from, what the research shows, what the risks are, and what legal options exist. Not fear. Not a sales pitch. Just the truth, as clearly as I can give it.
That's what this was for.
Primary sources: Andrew Huberman's podcast episode with Dr. Abud Bakri on peptides; Peter Attia's AMA #83 on peptide therapeutics; FDA regulatory documentation on compounding pharmacy enforcement and drug shortage resolution; WADA 2026 Prohibited List; peer-reviewed literature on BPC-157 human trial status and grey market peptide sourcing. My full GLP-1 deep-dive — the science, the access problem, and the harder cultural questions — is coming next.
Nothing here is medical advice. I'm a massage therapist and wellness educator sharing what I've learned. Please talk to a provider who actually knows you before making decisions about anything you put in your body.